IXCHIQ®Chikungunya vaccine (live) overview
What is IXCHIQ®?
IXCHIQ® is a live vaccine licensed to help prevent chikungunya.1 It is indicated in the UK for active immunisation for the prevention of disease caused by CHIKV in individuals aged 18 years to 59 years.1
Chikungunya is a mosquito-borne disease that can cause debilitating symptoms for months or years.2,3
Contraindications
The vaccine should not be given to individuals who are immunodeficient, immunosuppressed, suffer from hypertension, cardiovascular disease, diabetes mellitus and/or chronic kidney disease (CKD), or with a hypersensitivity to any component of the vaccine.1
Caution is advised when administering the vaccine to individuals with two or more underlying chronic health conditions.1
For more information about special warnings and precautions for use, please refer to the Summary of Product Characteristics.
IXCHIQ® Key facts
Live vaccine against CHIKV1
IXCHIQ® is a live vaccine licensed to help prevent chikungunya.1Can provide an immune response up to two years*4,5
In a pivotal phase III trial†, a single dose of IXCHIQ® induced a seroresponse‡ in 98.9% of participants after 28 days (95% CI 96.7–99.8; p<0.0001). In a Phase IIIb trial involving the same patients (n=316), seroresponse rate was 96.8% (95% CI 94.3–98.5) after 24 months.4,5Most adverse reactions were mild to moderate in the pivotal Phase III trial4§
Most also resolved in 2–3 days.4Single dose administration1
IXCHIQ® is administered in one injectable dose of vaccine, no later than 30 days prior to travel.1Please note
*No efficacy data are available for IXCHIQ®. The clinical efficacy of IXCHIQ® was inferred from a post-vaccination CHIKV-specific neutralizing antibody titre threshold. A threshold of CHIKV-specific neutralizing antibody μPRNT50 titre of ≥150 was selected as surrogate marker for protection, referred to as seroresponse. This threshold was determined from a non-human primate passive transfer study in which animals with titres ≥150 were protected against wild-type CHIKV infections and had undetectable virus in blood during 14 days after the challenge. In addition, the threshold was supported by data obtained from a prospective human sero-epidemiological study.1
†Phase III trial was a multicentre, randomised, placebo-controlled, double-blinded pivotal study to evaluate safety and immunogenicity of IXCHIQ® vaccine in 4128 participants across 43 professional vaccine trial sites in the US (266 patients who received IXCHIQ® were assessed for immunogenicity).4
‡Defined as CHIKV neutralising antibody titre ≥150 by μPRNT50 (50% reduction in a micro plaque reduction neutralisation test) for baseline participants 28 days after first vaccination. The lower bound of the 95% CI for the SRR at Day 29 in IXCHIQ® group needed to exceed 70% neutralising antibody titres determined using μPRNT50 assay.1,4
§Data from the landmark Phase III trial of 4128 participants at 43 study sites (safety population consisted of 4115 individuals).4
References
- IXCHIQ. Summary of Product Characteristics. February 2026. Available at: https://www.medicines.org.uk/emc/product/100652/smpc. Accessed: March 2026.
- Paixão, E.S., Rodrigues, L.C., Costa, M. da C.N., et al. Chikungunya chronic disease: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. 2018;112(7):301–316.
- World Health Organization. Chikungunya fact sheet. April 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/chikungunya. Accessed: March 2026.
- Schneider, M., Narciso-Abraham, M., Hadl, S., et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023;401(10394):2138–2147.
- McMahon, R., Toepfer, S., Sattler, N., et al. Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study. Lancet Infectious Diseases. 2024;24(12):1383–1392.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Valneva UK Ltd Medical Information department on Tel: 01506 446608 or via email: safety@valneva.com